Autoimmune hepatitis: Contrasts and comparisons in children and adults - A comprehensive review

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 7-16

  Floreani, Annarosa ^a   Liberal, Rodrigo ^b   Vergani, Diego ^b   Mieli Vergani, Giorgina ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmune hepatitis; Autoimmune sclerosing cholangitis; Azathioprine; Corticosteroids; De novo autoimmune hepatitis post liver transplant; Mycophenolate mofetil

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; HLA DR ANTIGEN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

ACUTE GRAFT REJECTION; ACUTE HEPATITIS; ACUTE LIVER FAILURE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CHOLANGIOGRAPHY; CHRONIC LIVER DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG INDUCED HEADACHE; END STAGE LIVER DISEASE; FAMILY HISTORY; FOLLOW UP; GENETIC PREDISPOSITION; HAIR LOSS; HEPATITIS A; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY MICROSOME; LIVER BIOPSY; LIVER CYTOSOL; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LONG TERM CARE; LONG TERM SURVIVAL; NAUSEA; NEUTROPENIA; PERSISTENT INFECTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SCLEROSING CHOLANGITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AUTOIMMUNE HEPATITIS; AUTOIMMUNE SCLEROSING CHOLANGITIS; AZATHIOPRINE; CORTICOSTEROIDS; DE NOVO AUTOIMMUNE HEPATITIS POST LIVER TRANSPLANT; MYCOPHENOLATE MOFETIL;

ADULT; AGE FACTORS; AUTOANTIBODIES; CHILD; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; MODELS, IMMUNOLOGICAL; SEX FACTORS;

EID: 84886237697     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.08.004     Document Type: Review

References (100)

1. Mieli-Vergani G., Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011, 8:320-329.
2. Gregorio G.V., Portmann B., Reid F., Donaldson P.T., Doherty D.G., McCartney M., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
3. Martini E., Abuaf N., Cavalli F., Durand V., Johanet C., Homberg J.C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988, 8:1662-1666.
4. Ma Y., Okamoto M., Thomas M.G., Bogdanos D.P., Lopes A.R., Portmann B., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
5. Gregorio G.V., Portmann B., Karani J., Harrison P., Donaldson P.T., Vergani D., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
6. Donaldson P.T. Genetics in autoimmune hepatitis. Semin Liver Dis 2002, 22:353-364.
7. Ma Y., Bogdanos D.P., Hussain M.J., Underhill J., Bansal S., Longhi M.S., et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006, 130:868-882.
8. Fainboim L., Canero Velasco M.C., Marcos C.Y., Ciocca M., Roy A., Theiler G., et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB 1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001, 33:1512-1517.
9. Pando M., Larriba J., Fernandez G.C., Fainboim H., Ciocca M., Ramonet M., et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999, 30:1374-1380.
10. Vergani D., Wells L., Larcher V.F., Nasaruddin B.A., Davies E.T., Mieli-Vergani G., et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985, 2:294-298.
11. Liston A., Lesage S., Gray D.H., Boyd R.L., Goodnow C.C. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev 2005, 204:87-101.
12. Simmonds M.J., Gough S.C. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull 2004, 71:93-113.
13. Ahonen P., Myllarniemi S., Sipila I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. NEngl J Med 1990, 322:1829-1836.
14. Underhill J.A., Ma Y., Bogdanos D.P., Cheeseman P., Mieli-Vergani G., Vergani D. Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis. JHepatol 2002, 36(Suppl.1):156. (Abs).
15. Johnson P.J., McFarlane I.G. Meeting report: International autoimmune hepatitis group. Hepatology 1993, 18:998-1005.
16. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. JHepatol 1999, 31:929-938.
17. Ebbeson R.L., Schreiber R.A. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?. Clin Gastroenterol Hepatol 2004, 2:935-940.
18. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
19. Hiejima E., Komatsu H., Sogo T., Inui A., Fujisawa T. Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children. JPediatr Gastroenterol Nutr 2011, 52:470-473.
20. Ferreira A.R., Roquete M.L., Toppa N.H., de Castro L.P., Fagundes E.D., Penna F.J. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis. JPediatr Gastroenterol Nutr 2008, 46:65-70.
21. Kerkar N., Annunziato R.A., Foley L., Schmeidler J., Rumbo C., Emre S., et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. JPediatr Gastroenterol Nutr 2006, 43:629-634.
22. Samaroo B., Samyn M., Buchanan C., Mieli-Vergani G. Long-term daily oral treatment with prednisolone in children with autoimmune liver disease does not affect final adult height. Hepatology 2006, 44:438. (Abs).
23. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
24. Ferreira A.R., Roquete M.L., Penna F.J., Toppa N.H., Castro L.P. Type 1 autoimmune hepatitis in children and adolescents: assessment of immunosuppressive treatment withdrawal. JPediatr (Rio J) 2005, 81:343-348.
25. Scalori A., Heneghon M.A., Hadzic N.D., Vergani D., Mieli-Vergani G. Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis; a 13 years follow-up study. Hepatology 2007, 46:555. (Abs).
26. Alvarez F., Ciocca M., Canero-Velasco C., Ramonet M., de Davila M.T., Cuarterolo M., et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. JHepatol 1999, 30:222-227.
27. Cuarterolo M., Ciocca M., Velasco C.C., Ramonet M., Gonzalez T., Lopez S., et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. JPediatr Gastroenterol Nutr 2006, 43:635-639.
28. Mieli-Vergani G., Vergani D. Autoimmune hepatitis in children. Clin Liver Dis 2002, 6:623-634.
29. Lennard L., Van Loon J.A., Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46:149-154.
30. Czaja A.J. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008, 7:319-333.
31. Rumbo C., Emerick K.M., Emre S., Shneider B.L. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. JPediatr Gastroenterol Nutr 2002, 35:391-398.
32. Manns M.P., Woynarowski M., Kreisel W., Lurie Y., Rust C., Zuckerman E., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010, 139:1198-1206.
33. Woynarowski M., Nemeth A., Baruch Y., Koletzko S., Melter M., Rodeck B., et al. Budesonide 3 Mg Tid in the treatment of autoimmune hepatitis (Aih) in adolescents, a subgroup analysis of the European Aih-Buc-study. JHepatol 2011, 54:S14.
34. Aw M.M., Dhawan A., Samyn M., Bargiota A., Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. JHepatol 2009, 51:156-160.
35. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., Chapman R.W. Apreliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
36. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
37. Gregorio G.V., McFarlane B., Bracken P., Vergani D., Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002, 35:515-519.
38. Liberal R., Longhi M.S., Grant C.R., Mieli-Vergani G., Vergani D. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol 2012, 10:346-353.
39. Kerkar N., Hadzic N., Davies E.T., Portmann B., Donaldson P.T., Rela M., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
40. Kerkar N., Dugan C., Rumbo C., Morotti R.A., Gondolesi G., Shneider B.L., et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005, 5:1085-1089.
41. Vergani D., Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002, 36:271-276.
42. Mieli-Vergani G., Vergani D. De novo autoimmune hepatitis after liver transplantation. JHepatol 2004, 40:3-7.
43. Al-Chalabi T., Underhill J.A., Portmann B.C., McFarlane I.G., Heneghan M.A. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. JHepatol 2008, 48:140-147.
44. Strassburg C.P., Manns M.P. Therapy of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011, 25:673-687.
45. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
46. Werner M., Prytz H., Ohlsson B., Almer S., Bjornsson E., Bergquist A., et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008, 43:1232-1240.
47. Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010, 139:58-72. e4.
48. Jothimani D., Cramp M.E., Mitchell J.D., Cross T.J. Treatment of autoimmune hepatitis: a review of current and evolving therapies. JGastroenterol Hepatol 2011, 26:619-627.
49. Czaja A.J. Special reports: autoimmune hepatitis. Curr Treat Options Gastroenterol 1999, 2:423-436.
50. Czaja A.J. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 2010, 16:934-947.
51. Danielsson A., Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994, 8:585-590.
52. Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119:1312-1316.
53. Wiegand J., Schuler A., Kanzler S., Lohse A., Beuers U., Kreisel W., et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005, 25:927-934.
54. Richardson P.D., James P.D., Ryder S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. JHepatol 2000, 33:371-375.
55. Devlin S.M., Swain M.G., Urbanski S.J., Burak K.W. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004, 18:321-326.
56. Brunt E.M., Di Bisceglie A.M. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum Pathol 2004, 35:509-512.
57. Chatur N., Ramji A., Bain V.G., Ma M.M., Marotta P.J., Ghent C.N., et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005, 25:723-727.
58. Czaja A.J., Carpenter H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. JClin Gastroenterol 2005, 39:819-825.
59. Inductivo-Yu I., Adams A., Gish R.G., Wakil A., Bzowej N.H., Frederick R.T., et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007, 5:799-802.
60. Hlivko J.T., Shiffman M.L., Stravitz R.T., Luketic V.A., Sanyal A.J., Fuchs M., et al. Asingle center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:1036-1040.
61. Hennes E.M., Oo Y.H., Schramm C., Denzer U., Buggisch P., Wiegard C., et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol 2008, 103:3063-3070.
62. Wolf D.C., Bojito L., Facciuto M., Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009, 54:2519-2522.
63. Strassburg C.P., Bahr M.J., Becker T., Klempnauer J., Manns M.P. Progress in immunosuppression. Chirurgia 2008, 79:149-156.
64. Malekzadeh R., Nasseri-Moghaddam S., Kaviani M.J., Taheri H., Kamalian N., Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001, 46:1321-1327.
65. Fernandes N.F., Redeker A.G., Vierling J.M., Villamil F.G., Fong T.L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999, 94:241-248.
66. Heneghan M.A., Rizzi P., McFarlane I.G., Portmann B., Harrison P.M. Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction. Gut 1999, 44:A61. (Abs).
67. Van Thiel D.H., Wright H., Carroll P., Abu-Elmagd K., Rodriguez-Rilo H., McMichael J., et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:771-776.
68. Aqel B.A., Machicao V., Rosser B., Satyanarayana R., Harnois D.M., Dickson R.C. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. JClin Gastroenterol 2004, 38:805-809.
69. Larsen F.S., Vainer B., Eefsen M., Bjerring P.N., Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007, 13:3232-3236.
70. Maggiore G., De Benedetti F., Massa M., Pignatti P., Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. JPediatr Gastroenterol Nutr 1995, 20:23-27.
71. Czaja A.J., Cookson S., Constantini P.K., Clare M., Underhill J.A., Donaldson P.T. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999, 117:645-652.
72. Cookson S., Constantini P.K., Clare M., Underhill J.A., Bernal W., Czaja A.J., et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999, 30:851-856.
73. Weiler-Normann C., Wiegard C., Schramm C., Lohse A.W. Acase of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009, 104:2877-2878.
74. Fujii K., Rokutanda R., Osugi Y., Koyama Y., Ota T. Adult-onset Still's disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med 2012, 51:1125-1128.
75. Weiler-Normann C., Schramm C., Quaas A., Wiegard C., Glaubke C., Pannicke N., et al. Infliximab as a rescue-treatment in difficult-to-treat autoimmune hepatitis. JHepatol 2012.
76. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: Is there a real relationship?. Autoimmun Rev 2012.
77. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.
78. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells invivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
79. Dorner T., Isenberg D., Jayne D., Wiendl H., Zillikens D., Burmester G. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9:82-89.
80. Tranchida P., Bayerl M., Voelpel M.J., Palutke M. Testicular ischemia due to intravascular large B-cell lymphoma: a novel presentation in an immunosuppressed individual. Int J Surg Pathol 2003, 11:319-324.
81. Barth E., Clawson J. Acase of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol 2010, 4:502-509.
82. Santos E.S., Arosemena L.R., Raez L.E., O'Brien C., Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006, 26:625-629.
83. Evans J.T., Shepard M.M., Oates J.C., Self S.E., Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. JClin Gastroenterol 2008, 42:862-863.
84. Carey E.J., Somaratne K., Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil 2011, 139:1484-1487.
85. Burak K.W., Swain M.G., Santodomingo-Garzon T., Lee S.S., Urbanski S.J., Myers R.P. Rituximab for refractory autoimmune hepatitis: final results of a phase 1 study. JHepatol 2011, 54:S507. (Abs).
86. Longhi M.S., Hussain M.J., Mitry R.R., Arora S.K., Mieli-Vergani G., Vergani D., et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. JImmunol 2006, 176:4484-4491.
87. Ferri S., Longhi M.S., De Molo C., Lalanne C., Muratori P., Granito A., et al. Amultifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010, 52:999-1007.
88. Liberal R., Longhi M.S., Mieli-Vergani G., Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011, 25:653-664.
89. Longhi M.S., Ma Y., Mitry R.R., Bogdanos D.P., Heneghan M., Cheeseman P., et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. JAutoimmun 2005, 25:63-71.
90. Longhi M.S., Meda F., Wang P., Samyn M., Mieli-Vergani G., Vergani D., et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008, 47:581-591.
91. Longhi M.S., Hussain M.J., Bogdanos D.P., Quaglia A., Mieli-Vergani G., Ma Y., et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46:472-484.
92. Longhi M.S., Hussain M.J., Kwok W.W., Mieli-Vergani G., Ma Y., Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011, 53:536-547.
93. Boberg K.M., Chapman R.W., Hirschfield G.M., Lohse A.W., Manns M.P., Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. JHepatol 2011, 54:374-385.
94. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
95. Joshi S., Cauch-Dudek K., Wanless I.R., Lindor K.D., Jorgensen R., Batts K., et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002, 35:409-413.
96. Al-Chalabi T., Portmann B.C., Bernal W., McFarlane I.G., Heneghan M.A. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008, 28:209-220.
97. Floreani A., Rizzotto E.R., Ferrara F., Carderi I., Caroli D., Blasone L., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516-1522.
98. Trivedi P.J., Hirschfield G.M. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 2012, 36:517-533.
99. Boberg K.M., Egeland T., Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003, 38:991-995.
100. Olsson R., Glaumann H., Almer S., Broome U., Lebrun B., Bergquist A., et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009, 20:190-196.